UNSPSC 51132211: Acetaminophen/pamabrom/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132211 Acetaminophen/pamabrom/pyrilamine is a Commodity code, but recent state and local procurement activity tagged under it does not align with this specific pharmaceutical formulation. The three most recent opportunities solicited under this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products broadly — none of which are acetaminophen/pamabrom/pyrilamine combinations. This suggests either a tagging error in the source data or a state and local procurement practice that uses the code for a broader family of over-the-counter and pharmaceutical products rather than this specific formulation.

Recent activity shows issuing bodies across state health agencies, county health systems, and cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response date. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore direct-to-manufacturer prescription fulfillment capabilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. Geographic activity spans Florida, Texas, and the upper Midwest, though the code shows minimal recent procurement volume and the misalignment between the code name and actual solicitation scope suggests this is not an active buying category in state and local markets.